New Appointments Bring Extensive Ocular Drug Delivery, Strategy and Scientific Expertise to Advance the Sustained Release of Biologics and Small Molecules into the Eye to Treat Sight-Threatening Eye Diseases Belfast, Northern Ireland – 23 February 2021 – Re-Vana...
In the OIS Podcast, ExSight Ventures discuss why they invested into Re-Vana. Here is the segment where they discuss Re-Vana Therapeutics: Download the excerpt using this link.Listen to the Full Podcast Here (Discussion of Re-Vana commences at 43 minutes.)...
Michael O’Rourke CEO presents online at the OIS Drug Delivery Forum – 5th November 2020
Michael O'Rourke, CEO of Re-Vana Therapeutics, presents online at the Ophthalmology Futures Forums on Wednesday, September 30th, 2020. https://youtu.be/iUBtmg7jCWo
Welcome to BusinessCloud’s Northern Ireland Tech 50 ranking for 2020. Cemetery software firm PlotBox tops our inaugural ranking of Northern Ireland’s most innovative technology companies. See Full Article at BusinessCloud >>
See the entire Opthamology Future Forum Advisory Board at: https://www.ophthalmology-futures.com/about-us/advisory-board/
Belfast, Northern Ireland – June 2, 2020 – Re-Vana Therapeutics Ltd, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, today announced that it has closed $3.25...
… The late-morning session, titled “New Horizons in Drug Delivery,” will focus exciting innovations in drug delivery systems, with moderators Michael Robinson, MD, vice president and Therapeutic Area head, Allergan; and James C. Tsai, MD, MBA, National Eye Health...
Queen’s University Belfast has came top of University rankings, beating both Oxford and Cambridge, to be recognised as the most entrepreneurial University in the UK, according to a new report published by Octopus Ventures.
Re-Vana has developed a novel disruptive photocrosslinked proprietary biodegradable sustained release drug delivery implant, EyeLief. The implant will provide significant clinical benefits over current monthly intravitreal injections. Following injection into the eye,...
Michael O'Rourke CEO presents Re-Vana at the OIS ASRS in Chicago 25th July 2019 (5 mins) Presentation
Michael O'Rourke CEO interviewed on his insights into drug delivery trends and what makes Re-Vana different! (11 mins)